739 related articles for article (PubMed ID: 22752862)
1. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
[TBL] [Abstract][Full Text] [Related]
2. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
[TBL] [Abstract][Full Text] [Related]
3. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.
Figueroa I; Johnson S; Sambol SP; Goldstein EJ; Citron DM; Gerding DN
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S104-9. PubMed ID: 22752857
[TBL] [Abstract][Full Text] [Related]
4. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.
Warren CA; van Opstal EJ; Riggins MS; Li Y; Moore JH; Kolling GL; Guerrant RL; Hoffman PS
Antimicrob Agents Chemother; 2013 Feb; 57(2):689-96. PubMed ID: 23147742
[TBL] [Abstract][Full Text] [Related]
5. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
Crook DW; Walker AS; Kean Y; Weiss K; Cornely OA; Miller MA; Esposito R; Louie TJ; Stoesser NE; Young BC; Angus BJ; Gorbach SL; Peto TE;
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S93-103. PubMed ID: 22752871
[TBL] [Abstract][Full Text] [Related]
6. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.
Tannock GW; Munro K; Taylor C; Lawley B; Young W; Byrne B; Emery J; Louie T
Microbiology (Reading); 2010 Nov; 156(Pt 11):3354-3359. PubMed ID: 20724385
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
[TBL] [Abstract][Full Text] [Related]
8. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin.
Thabit AK; Alam MJ; Khaleduzzaman M; Garey KW; Nicolau DP
Ann Clin Microbiol Antimicrob; 2016 Apr; 15():22. PubMed ID: 27071986
[TBL] [Abstract][Full Text] [Related]
9. Differences of the Fecal Microflora With Clostridium difficile Therapies.
Louie TJ; Byrne B; Emery J; Ward L; Krulicki W; Nguyen D; Wu K; Cannon K
Clin Infect Dis; 2015 May; 60 Suppl 2():S91-7. PubMed ID: 25922407
[TBL] [Abstract][Full Text] [Related]
10. Is shorter also better in the treatment of Clostridioides difficile infection?
Duricek M; Halmova K; Krutova M; Sykorova B; Benes J
J Antimicrob Chemother; 2024 Jun; 79(6):1413-1417. PubMed ID: 38661207
[TBL] [Abstract][Full Text] [Related]
11. Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
[TBL] [Abstract][Full Text] [Related]
12. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.
Petrella LA; Sambol SP; Cheknis A; Nagaro K; Kean Y; Sears PS; Babakhani F; Johnson S; Gerding DN
Clin Infect Dis; 2012 Aug; 55(3):351-7. PubMed ID: 22523271
[TBL] [Abstract][Full Text] [Related]
13. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
Crawford T; Huesgen E; Danziger L
Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
[TBL] [Abstract][Full Text] [Related]
14. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.
Nerandzic MM; Mullane K; Miller MA; Babakhani F; Donskey CJ
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S121-6. PubMed ID: 22752860
[TBL] [Abstract][Full Text] [Related]
15. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
Cornely OA
Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
[TBL] [Abstract][Full Text] [Related]
16. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile.
Eyre DW; Babakhani F; Griffiths D; Seddon J; Del Ojo Elias C; Gorbach SL; Peto TE; Crook DW; Walker AS
J Infect Dis; 2014 May; 209(9):1446-51. PubMed ID: 24218500
[TBL] [Abstract][Full Text] [Related]
17. An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections.
Rao K; Zhao Q; Bell J; Krishnan J; Henig O; Daniel J; Sawaya K; Albin O; Mills JP; Petty LA; Gregg K; Kaul D; Malani AN; Pogue J; Kaye KS
Clin Infect Dis; 2024 Feb; 78(2):277-282. PubMed ID: 37797310
[TBL] [Abstract][Full Text] [Related]
18. Effect of Fidaxomicin versus Vancomycin on Susceptibility to Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice.
Deshpande A; Hurless K; Cadnum JL; Chesnel L; Gao L; Chan L; Kundrapu S; Polinkovsky A; Donskey CJ
Antimicrob Agents Chemother; 2016 Jul; 60(7):3988-93. PubMed ID: 27090175
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).
Wolf J; Kalocsai K; Fortuny C; Lazar S; Bosis S; Korczowski B; Petit A; Bradford D; Croos-Dabrera R; Incera E; Melis J; van Maanen R
Clin Infect Dis; 2020 Dec; 71(10):2581-2588. PubMed ID: 31773143
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection.
Nathwani D; Cornely OA; Van Engen AK; Odufowora-Sita O; Retsa P; Odeyemi IA
J Antimicrob Chemother; 2014 Nov; 69(11):2901-12. PubMed ID: 25096079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
